Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo
Abstract
Corrected by: Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo Z Gastroenterol 2014; 52(01): 64-64 DOI: 10.1055/s-0034-1366796 Zusammenfassung Hintergrund: Therapiestudien mit bakteriellen Produkten (Probiotika) haben beim Reizdarmsyndrom (RDS) bislang widersprüchliche Ergebnisse erbracht, und E.-coli-Präparate wurden bislang nicht eingesetzt. Methoden: Bei insgesamt 298 Patienten mit Symptomen im unteren Gastrointestinaltrakt, die als Reizdarmsyndrom diagnostiziert worden waren, wurden doppelblind und randomisiert für 8 Wochen mit dem Probiotikum Symbioflor®-2 (Symbiopharm GmbH, Herborn), einem Escherichia-coli-Produkt (N = 148) oder mit Placebo (n = 150) eingesetzt. Die Patienten wurden wöchentlich von ihrem Hausarzt gesehen, der das Vorhandensein zentraler RDS-Symptome überprüfte. Ein abdomineller Schmerzscore (APS) und eine allgemeiner Symptomscore (GSS) waren die primären Endpunkte der Studie und als Responder wurden diejenigen gewertet, die an mehr als einem Zeitpunkt keine Symptome mehr aufwiesen. Ergebnisse: Die Response-Rate betrug 27 / 148 (18,2 %) für das Medikament und 7 / 150 (4,67 %) für Placebo im Hinblick auf den GSS (p = 0,000397); die entsprechende Effektivität für den APS war 28 / 148 (18,9 %) für Symbioflor und 10 / 150 (6,67 %) für Placebo (p = 0,001649). Post-hoc fanden sich keine Unterschiede in der Medikamentenwirksamkeit zwischen den Geschlechtern und in unterschiedlichen Altersgruppen. Schlussfolgerung: Die Behandlung des RDS mit dem probiotischen Medikament Symbioflor-2 ist wirksam und einer Placebobehandlung überlegen; sie reduziert die typischen RDS-Symptome bei diesen Patienten, die von Gastroenterologen und Allgemeinärzten gesehen werden.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Specific probiotics help relieve overall symptom burden in some patients with IBS, with high grade of evidence.
“Specific probiotics help relieve overall symptom burden in some patients with IBS High [147,149,150,152,156-157,169, 174,176-178]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [176]
With specific probiotics, improvement of symptoms has been shown to lead to improvement in some aspects of health-related quality of life, with moderate grade of evidence.
“With specific probiotics, improvement of symptoms has been shown to lead to improvement in some aspects of health-related quality of life Moderate [147,150,152,155,169-170,174,176-177,179-180,183-184,186]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [176]
Cited by
Sorted by citations
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747 · see citing works
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 648 · see citing works
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619 · see citing works
“…Total events Pineton de Chambrun (2015) 2015 2016 46 135 181 196 100 192 292 56 140 100 187 287 16.9% 83.1% 100.0% 0.82 [0.62, 1.08] 0.94 [0.83, 1.06] 0.92 [0.82, 1.03] Spiller (2016) Enck (2009) Gade (1989) 20 32 32 19 19 22 22 100.0% 100.0% 0.72 [0.53, 0.99] 0.72 [0.53, 0.99] 0.1 0.2…”
BackgroundInfluentialAmerican College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388 · see citing works
Didari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356 · see citing works
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320 · see citing works
Role of Probiotics in health improvement, infection control and disease treatment and management
Amara, A. A. A. F., & Shibl, A. M. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.001 · Cited by 311 · see citing works
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 272 · see citing works
“An improvement in IBS symptoms was noted in 95% of patients in the LP299V group vs 15% of patients in the placebo group (P .0001).”
InfluentialTherapeutical use of probiotic formulations in clinical practice
Iannitti, T., & Palmieri, B. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2010.05.004 · Cited by 262 · see citing works
Layer, P., Andresen, V., Pehl, C., Allescher, H. ‐., Bischoff, S., Claßen, M., Enck, P., Frieling, T., Haag, S., Holtmann, G., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1245976 · Cited by 231 · see citing works
Self-citationIrritable Bowel Syndrome, Gut Microbiota and Probiotics
Lee, B. J., & Bak, Y. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.3.252 · Cited by 229 · see citing works
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212 · see citing works
“ritus and diarrhoea) occurred equally in the probiotic and placebo groups.(27) In a study of patients with IBS,”
BackgroundWorld Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209 · see citing works
Dietary and pharmacological treatment of abdominal pain in IBS
Camilleri, M., & Boeckxstaens, G. (2017) · Gut · doi:10.1136/gutjnl-2016-313425 · Cited by 144 · see citing works
The microbiota-gut-brain axis in functional gastrointestinal disorders
De Palma, G., Collins, S. M., & Bercik, P. (2014) · Gut Microbes · doi:10.4161/gmic.29417 · Cited by 157 · see citing works
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C., Cole, O., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J. ‐., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14539 · Cited by 154 · see citing works
Insights from 100 years of research with probiotic E. coli
Wassenaar, T. M. (2016) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2016.00029 · Cited by 147 · see citing works
“coli, comparing the Symbiofl or 2 study mentioned above [22] with an EcN study [24]; in the meta-analysis, the effects were positive and comparable [25].”
MethodResultAGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 135 · see citing works
Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.859967 · Cited by 125 · see citing works
“Among the included studies, 29 RCTs (Niedzielin et al., 2001; Bauserman and Michail, 2005; Niv et al., 2005; O’Mahony et al., 2005; Whorwell et al., 2006; Sinn et al., 2008; Enck et al., 2009; Ligaarden et al., 2010; Choi et al., 2011; Guglielmetti et al., 2011; Kabir et al., 2011; Dapoigny et al., 2012; Ducrotté et a…”
BackgroundHaller, D., Antoine, J., Bengmark, S., Enck, P., Rijkers, G. T., & Lenoir‐Wijnkoop, I. (2010) · Journal of Nutrition · doi:10.3945/jn.109.113746 · Cited by 105 · see citing works
Self-citationEffect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis
Ortiz-Lucas, M., Aurelio, T., Saz, P., & Sebastián, J. J. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000100005 · Cited by 103 · see citing works
“, 2009 (40) for diagnosis/diagnostic criteria Enck et al.”
InfluentialVisceral pain: gut microbiota, a new hope?
Pusceddu, M. M., & Gareau, M. G. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0476-7 · Cited by 100 · see citing works
Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Li, B., Li, L., Deng, H., Guo, J., Shu, H., & Zhang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00332 · Cited by 95 · see citing works
“…et al., 2015; Sun et al., 2018) evaluated a shorter duration (< 8 weeks) and 17 studies (Kim et al., 2003; Kajander et al., 2005; Enck et al., 2008; Enck et al., 2009; Hong et al., 2009; Simrén et al., 2010; Sondergaard et al., 2011; Cha et al., 2012; Kruis et al., 2012; Begtrup et al., 2013;…”
BackgroundMethodResultInfluentialNiu, H.-L., & Xiao, J. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.01.142 · Cited by 86 · see citing works
Irritable bowel syndrome: Role of food in pathogenesis and management
Morcos, A. I., Dinan, T. G., & Quigley, E. M. M. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00392.x · Cited by 81 · see citing works
Zschüttig, A., Zimmermann, K., Blom, J., Goesmann, A., Pöhlmann, C., & Gunzer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033351 · Cited by 81 · see citing works
“the product has been successfully used for the treatment of functional gastrointestinal disorders, in particular irritable bowel syndrome in adults and children [13,14].”
Self-citationLayer, P., Andresen, V., Allescher, H. ‐., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel‐Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 78 · see citing works
Singh, R. P., Shadan, A., & Ma, Y. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09992-8 · Cited by 81 · see citing works
Mazurak, N., Broelz, E. K., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 72 · see citing works
Self-citationHod, K., Sperber, A. D., Ron, Y., Boaz, M., Dickman, R. M., Berliner, S. A., Halpern, Z., Maharshak, N., & Dekel, R. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13037 · Cited by 70 · see citing works
Dysbiosis in Functional Bowel Disorders
Enck, P., & Mazurak, N. (2018) · Annals of Nutrition and Metabolism · doi:10.1159/000488773 · Cited by 68 · see citing works
Self-citationYoon, J. Y., Cha, J. M., Oh, J. K., Tan, P. L., Kim, S. H., Kwak, M. S., Jeon, J. W., & Shin, H. P. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5139-8 · Cited by 67 · see citing works
Felgner, S., Kocijancic, D., Frahm, M., Heise, U., Rohde, M., Zimmermann, K., Falk, C. S., Erhardt, M., & Weiß, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1382791 · Cited by 67 · see citing works
“Mutaflor or Symbioflor-2) as treatment of gastrointestinal disturbances.(24,25) Such prior encounters with bacteria that are related to the therapeutic strains may prohibit success of BMTT.”
BackgroundSelf-citationVisceral Pain and Gastrointestinal Microbiome
Chichlowski, M., & Rudolph, C. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15025 · Cited by 65 · see citing works
Treating irritable bowel syndrome with probiotics: the evidence
Parkes, G. C., Sanderson, J. D., & Whelan, K. (2010) · Proceedings of The Nutrition Society · doi:10.1017/s002966511000011x · Cited by 57 · see citing works
Gut Microbiota, Probiotics, and Human Health
Suvorov, A. N. (2013) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.32.81 · Cited by 56 · see citing works
What’s bugging your teen?—The microbiota and adolescent mental health
McVey Neufeld, K.-A., Luczynski, P., Seira Oriach, C., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.005 · Cited by 56 · see citing works
“…patients suffering from IBS (Niedzielin et al., 2001; Bauserman and Michail, 2005; Whorwell et al., 2006; Andriulli et al., 2008; Enck et al., 2008; Enck et al., 2009; Hun, 2009; Williams et al., 2009; Francavilla et al., 2010; Guglielmetti et al., 2011; Clarke et al., 2012; Cui and Hu, 2012;…”
Treatment of irritable bowel syndrome
Trinkley, K. E., & Nahata, M. C. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01177.x · Cited by 54 · see citing works
Guidelines on the management of irritable bowel syndrome
Pietrzak, A. M., Skrzydło-Radomańska, B., Mulak, A., Lipiński, M., Malecka-Panas, E. I., Reguła, J., & Rydzewska, G. M. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.78343 · Cited by 56 · see citing works
Roudsari, N. M., Lashgari, N., Momtaz, S., Farzaei, M. H., Marques, A. M., & Abdolghaffari, A. H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00284-1 · Cited by 50 · see citing works
The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome
Ringel, Y., & Ringel-Kulka, T. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31822d32d3 · Cited by 44 · see citing works
Pusceddu, M. M., Murray, K. M., & Gareau, M. G. (2018) · Current Pathobiology Reports · doi:10.1007/s40139-018-0160-3 · Cited by 42 · see citing works
Xie, P., Luo, M., Deng, X., Fan, J., & Xiong, L. (2023) · Nutrients · doi:10.3390/nu15173856 · Cited by 45 · see citing works
Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential
Kocijancic, D., Felgner, S., Frahm, M., Komoll, R., Iljazović, A., Pawar, V., Rohde, M., Heise, U., Zimmermann, K., Gunzer, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8027 · Cited by 41 · see citing works
“Since its isolation in 1956, Symbioflor-2 has a documented history of safe oral application, and was allocated to risk group 1 by the German authorities in 2011 [43, 44].”
BackgroundSelf-citationEfficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis
Jia, L.-Q., Sun, J.-R., Kong, C.-F., Qu, X.-K., Deng, C., & Lou, Y.-N. (2020) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_384_19 · Cited by 40 · see citing works
“coli was assessed in two trials (418 patients),[24,45] with little or no benefit detected compared with placebo (RR = 2.”
BackgroundEmerging Role of the Gut Microbiome in Irritable Bowel Syndrome
Singh, P., & Lembo, A. J. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.03.003 · Cited by 39 · see citing works
Irritable bowel syndrome: diagnosis and management
Masuy, I., Pannemans, J., & Tack, J. F. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02640-0 · Cited by 40 · see citing works
Corbitt, M., Campagnolo, N., Staines, D., & Marshall‐Gradisnik, S. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9397-8 · Cited by 37 · see citing works
Probiotics for management of functional abdominal pain disorders in children
Gordon, M. A., Wallace, C., Sinopoulou, V., & Akobeng, A. K. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012849.pub2 · Cited by 38 · see citing works
Probiotics use to treat irritable bowel syndrome
Hosseini, A., Nikfar, S., & Abdollahi, M. R. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707179 · Cited by 35 · see citing works
Šmid, A., Strniša, L., Bajc, K., Vujić-Podlipec, D., Matijašić, B. B., & Rogelj, I. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.04.031 · Cited by 33 · see citing works
A Review of Research Conducted with Probiotic<i> E. coli</i> Marketed as Symbioflor
Beimfohr, C. (2016) · International Journal of Bacteriology · doi:10.1155/2016/3535621 · Cited by 30 · see citing works
Mandarino, F. V., Sinagra, E., Barchi, A., Verga, M. C., Brinch, D., Raimondo, D., & Danese, S. (2023) · Microorganisms · doi:10.3390/microorganisms11051122 · Cited by 29 · see citing works
Probiotic treatment of irritable bowel syndrome in children
Martens, U., Enck, P., & Zieseniß, E. (2010) · PubMed Central · doi:10.3205/000096 · Cited by 28 · see citing works
Self-citationChen, M., Lu, Y., Xie, C.-R., Wang, X., Feng, S., Xiao, X.-Y., & Zheng, H. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000658 · Cited by 32 · see citing works
“The model – included 23 studies [20,22,23,28,33,36 – 38, 40, 43 , 48, 56, 60, 61 The moderator analysis showed that the treatment duration and the types of probiotics affected the effect size.”
MethodXie, C.-R., Tang, B., Shi, Y., Peng, W.-Y., Ye, K., Tao, Q., Yu, S., Zheng, H., & Chen, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853011 · Cited by 26 · see citing works
“Escherichia coli (Enck et al., 2009; Kruis et al., 2012) Saccharomyces, and Enterococcus (Gade and Thorn, 1989) were among the least effective interventions (Table 1).”
BackgroundMicroencapsulation of probiotic cells: applications in nutraceutic and food industry
Morales, M. E., & Ruiz, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804305-9.00016-6 · Cited by 27 · see citing works
Escherichia coli - Old and New Insights
Erjavec, M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95203 · Cited by 21 · see citing works
Probiotics for Human Health: Current Progress and Applications
Yadav, R., & Shukla, P. (2017) · Springer eBooks · doi:10.1007/978-981-10-5275-0_6 · Cited by 23 · see citing works
Zhang, W. X., Shi, L., Zhou, M. S., Wu, J., & Shi, H. Y. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001758 · Cited by 23 · see citing works
Enumeration of Escherichia coli in Probiotic Products
Zimmer, C., & Dorea, C. C. (2019) · Microorganisms · doi:10.3390/microorganisms7100437 · Cited by 17 · see citing works
“In randomized, controlled, double-blind clinical trials using human subjects, E. coli-based probiotics have been effective in reducing symptoms of constipation [7] and inflammatory bowel disease (IBD) [8], and were found to be equally as efficacious as the typical mesalazine treatment in preventing a relapse of ulcera…”
BackgroundAndresen, V., Pehl, C., Allescher, H. ‐., Bischoff, S. C., Enck, P., Frieling, T., Haag, S., Holtmann, G., Karaus, M., Keller, J., et al. (2011) · Cited by 17 · see citing works
Self-citationZschüttig, A., Auerbach, C., Meltke, S., Eichhorn, C., Brandt, M., Blom, J., Goesmann, A., Jarek, M., Scharfe, M., Zimmermann, K., et al. (2015) · Genome Announcements · doi:10.1128/genomea.01330-14 · Cited by 16 · see citing works
“G1/2 (DSM 16441) 5,090,326 252 JPKH00000000 pSYM10 (1,549), pSYM12 (7,111) KM107846 (pSYM10), KM107848 (pSYM12) G3/10 (DSM 16443) 4,999,267 12 JPKI00000000 pSYM1 (50,572), pSYM2 (4,197), pSYM3 (1,934), pSYM4 (1,304), pSYM5 (6,567), pSYM6 (10,433) JN887338 (pSYM1), KM107838 (pSYM2), KM107839 (pSYM3), KM107840 (pSYM4),…”
BackgroundSelf-citationThe role of gut microbiota in the treatment of irritable bowel syndrome
Leylabadlo, H. E., Heravi, F. S., Soltani, E., Abbasi, A., Kafil, H. S., Parsaei, M., Sanaie, S., Ahmadian, Z., & Ghotaslou, R. (2021) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000284 · Cited by 16 · see citing works
“298 subjects with IBS # IBS symptoms Symbioflor 2, an Escherichia coli product [154]”
BackgroundMillán, F., Rubio, L. S., Girón, I., Sánchez-Martín, F. M., Emiliani, E., & Angerri, O. (2020) · Urolithiasis · doi:10.1007/s00240-020-01181-y · Cited by 12 · see citing works
Bennett, W. E. (2015) · Drug Safety · doi:10.1007/s40264-015-0349-x · Cited by 12 · see citing works
“13 First, we constructed a dataset using all existing clinical trials that reported both efficacy and adverse drug events for both IBS(24-38) or IBD(40-49), as described in Figure 1 and Table 1.”
BackgroundMethodInfluentialZimmermann, C., Schild, M., Kunz, C., Zimmermann, K., & Kuntz, S. (2018) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2018.00004 · Cited by 12 · see citing works
“coli strains of the probiotic product Symbioflor 2, which is recommended for the treatment of irritable bowel syndrome [26, 42].”
BackgroundSelf-citationZeraattalab-Motlagh, S., Ranjbar, M., Mohammadi, H., & Adibi, P. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae107 · Cited by 11 · see citing works
Probiotics in the Rescue of Gut Inflammation
Ghosh, A. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814625-5.00006-6 · Cited by 10 · see citing works
Gendi, R., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9324 · Cited by 10 · see citing works
Escribano-Vázquez, U., Beimfohr, C., Bellet, D., Thomas, M., Zimmermann, K., Langella, P., & Cherbuy, C. (2020) · Microorganisms · doi:10.3390/microorganisms8040512 · Cited by 6 · see citing works
“Clinical trials showed that Symbioflor2® is effective in reducing symptoms of IBS patients in adults [11] and children [12].”
BackgroundSelf-citationDi Pierro, F., Sagheddu, V., Galletti, S., Casaroli, A., Labrini, E., Soldi, S., Cazzaniga, M., Bertuccioli, A., Matera, M., Cavecchia, I., et al. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10522-5 · Cited by 5 · see citing works
“Moreover, the strain E. coli A0 34/86, commercially available as Colinfant® New Born (Dyntec, Czech Republic), is mainly used in newborns for preventing infections and atopy [45, 46].”
Maslennikov, R. V., Gosteeva, E., Ananeva, V., Korshunova, L., Kravtsowa, A., Poluektova, E., Ulyanin, A. I., Sigidaev, A. S., Kikhasurova, P. M., & Ivashkin, V. T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031152 · Cited by 10 · see citing works
Schiefke, I. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.33.005359 · Cited by 5 · see citing works
“Antibiotics [12] and probiotics [15-18] have also been used and proved effective in some instances.”
Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
Stevenson, C., & Blaauw, R. (2011) · South African Journal of Clinical Nutrition · doi:10.1080/16070658.2011.11734353 · Cited by 5 · see citing works
Pastrana, L. M., González-González, R., Estévez, N., Pereira, L., Amado, I. R., Fuciños, P., Fuciños, C., Rúa, M. L., Alonso, E., & Troncoso, R. Á. (2016) · Elsevier eBooks · doi:10.1016/b978-0-444-63666-9.00007-8 · Cited by 9 · see citing works
The Role of Probiotics in the Treatment of Irritable Bowel Syndrome
Parkes, G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374938-3.00030-x · Cited by 4 · see citing works
Probiotics and prebiotics, including fibers and medicinal foods
Jana, T., Acker, B. W., & Cash, B. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00042-x · Cited by 4 · see citing works
Potential of Escherichia coli Probiotics for Improved Health and Disease Management
Gattupalli, N., & Gattupalli, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100380 · Cited by 4 · see citing works
“Symbioflor-2 is effective in reducing symptoms of irritable bowel syndrome [34].”
BackgroundEffectiveness Of Probiotics In Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis
Nikfar, S., Mozafari, S., Didari, T., & Abdollahi, M. R. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.799 · Cited by 3 · see citing works
Irritable bowel syndrome therapy in Vietnam with probiotic enterococci
Ермоленко, Е. И., Котылева, М. П., Tsapieva, A., Karaseva, A. B., Bui, T. L. A., & Suvorov, A. N. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-196-12-35-43 · Cited by 4 · see citing works
Modern aspects of the management of patients with irritable bowel syndrome
Tsukanov, V. V., Vasyutin, A. V., & Tonkikh, Y. L. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-5-22-28 · Cited by 5 · see citing works
Actualidades en la fisiopatología del síndrome de intestino irritable: el papel de las infecciones
Remes-Troche, J. M. (2012) · Medicina Interna de México · Cited by 3 · see citing works
Probiotics as Anti-Inflammatory Agents in Inflammatory Bowel Disease and Irritable Bowel Syndrome
Sharma, V., & Sharma, P. (2021) · Springer eBooks · doi:10.1007/978-981-33-6236-9_5 · Cited by 3 · see citing works
Hinse, M., Thronicke, A., Berghöfer, A., & Matthes, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277880 · Cited by 3 · see citing works
The Role of Probiotics, Prebiotics and Synbiotics in Adult Gastrointestinal Health
Chieng, J. Y., & Yan, P. (2022) · Gastroenterology & Hepatology Letters · doi:10.18063/ghl.v3i2.278 · Cited by 3 · see citing works
“Then, Enck recruited another 298 IBS patients, who were assigned to an eight-week trial to receive either single probiotic preparation containing E. coli (DSM 17252) (n = 148) or placebo (n = 150) [39] .”
MethodReizdarmsyndrom – neue Leitlinie und Stellenwert von Probiotika
Krammer, H., Schmidt-Lauber, M., & Krammer, J. (2023) · coloproctology · doi:10.1007/s00053-023-00726-0 · Cited by 2 · see citing works
Reid, G. (2013) · Springer eBooks · doi:10.1007/978-3-642-30144-5_89 · Cited by 1 · see citing works
Irritable bowel syndrome dietary management
Staudacher, H. M., & Parkes, G. C. (2014) · Wiley eBooks · doi:10.1002/9781118872796.ch3.19 · Cited by 1 · see citing works
[How the studies of the reproduction process contributed to the appearance of neuroendocrinology].
Zárate, A., Saucedo, R., & Hernández, M. (2006) · PubMed · Cited by 1 · see citing works
Impact de souches commensales et probiotiques d'Escherichia coli sur la physiopathologie de l'hôte
Escribano-Vázquez, U. (2018) · doi:10.70675/ae439ff5z4d13z4af2za21az2572e5749b15 · Cited by 1 · see citing works
[Irritable bowel syndrome: a functional disorder?].
Man, F., & Fernández, L. M. B. (2013) · PubMed
Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
Stevenson, C., & Blaauw, R. (2012) · Pharmacy management
Layer, P. (2010) · Springer eBooks · doi:10.1007/978-3-642-11635-3_9
Khosruzzaman, S. M., Ishaque, S. M., Ahmed, D. S., Kabir, M. A., Ahmed, E. U., & Jannat, S. N. E. (2017) · Journal of Chittagong Medical College Teachers Association · doi:10.3329/jcmcta.v27i2.62362
“The responder rate was significantly higher in probiotics-treated groups when global symptom improvement was considered [36,43].”
BackgroundWie wirksam sind Probiotika bei Reizdarm, CED und C.-difficile-Infektionen?
Toader, J., & Erhardt, A. (2023) · Gastro-News · doi:10.1007/s15036-023-3240-0
“In allen drei Studien konnte gegenüber Placebo eine Überlegenheit der probiotischen Therapie ge- Probiotischer Stamm n Studienergebnisse Bifidobacterium infantis 35624 302 keine signifikante Verbesserung des mittleren Schweregrades der Symptome von Bauchbeschwerden und Blähungen [5] Bifidobacterium longum NCC3001 44 V…”
BackgroundKim, Y. W., Park, S.-Y., Kang, S. J., Lee, M. W., Choi, Y., Kim, B. Y., Choi, M., Shin, C. M., Kim, Y. W., Kim, N., et al. (2026) · Sex- and Gender-Specific Biomedicine · doi:10.65400/sgbm.2026.1.2.85
- Authors
- Enck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- ORCID
- Enck, P
- Venue
- Zeitschrift für Gastroenterologie
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009-02
- Volume
- 47
- Issue
- 02
- Pages
- 209-214
- ISSN
- 0044-2771 (ISSN-L)
- 1439-7803
- OpenAlex
- W1999135384
- Cited by
- 100
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 4 · 2018: 12 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 7 · 2012: 4
- FWCI
- 6.02
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Zeitschrift für Gastroenterologie (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, Escherichia coli, abdominal pain, general symptoms, placebo comparison, treatment response rate, lower gastrointestinal symptoms, sex differences, age differences
- MeSH terms
- Adult, Age Factors, Escherichia coli, Female, Gastroenterology, Humans, Male, Middle Aged, Placebos, Primary Health Care, Sex Factors, Time Factors, Abdominal Pain, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
